Author(s)

Zhimei Huang ¹, Jiayao Zhao ², Zhengchun Liu ³, Xiuli Liu ⁴

Affiliation(s)

¹ Guangxi Clinical Medical Research Center for Neurological Diseases, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China
² Guilin People's Hospital, Guilin, Guangxi, China
³ Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China
⁴ Guangxi Medical and Health Key Discipline Construction Project, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China

Corresponding Author

ABSTRACT

T cell co-stimulatory receptor OX40 (CD134) and its ligand OX40L (CD252) are members of the tumor necrosis factor receptor/tumor necrosis factor superfamily (TNFRSF/TNFSF), respectively. OX40 is mainly expressed on activated T cells, including CD4, CD8, helper T cells, and regulatory T cells (Tregs). OX40L is mainly expressed on antigen-presenting cells (APCs). OX40/OX40L are a pair of co-stimulatory molecules that play vital roles in both initial and secondary T-cell responses. They are critical for the maintenance of T-cell proliferation, survival, and the formation of memory T-cells, which affects cellular immunity, humoral immune response, and immune tolerance. It is pivotal in mediating the occurrence and development of tumor immune response. Preclinical animal studies have demonstrated that OX40-targeted agonists can exert significant anti-tumor effects when used alone or in combination with other treatment methods. Multiple early clinical studies targeting OX40/OX40L are currently underway. This article will review molecular biological characteristics, mechanisms of action, and anti-tumor applications.

KEYWORDS

CITE THIS PAPER

Zhimei Huang, Jiayao Zhao, Zhengchun Liu, Xiuli Liu, Research Progress of OX40/OX40L in Tumor Immunotherapy. Transactions on Cancer (2024) Vol. 5: 72-78. DOI: http://dx.doi.org/10.23977/tranc.2024.050110.

REFERENCES

[1] Webb GJ, Hirschfield GM, Lane PJL. (2016)OX40, OX40L and Autoimmunity: a Comprehensive Review. Clinical Reviews in Allergy & Immunology, 50, 312-332.
[2] Walker LSK, Gulbranson-Judge A, Flynn S, Brocker T, Lane PJL. (2000)Co-stimulation and selection for T-cell help for germinal centres: The role of CD28 and OX40. Immunology Today, 21, 333-337.
[3] Metzger TC, Long H, Potluri S, Pertel T, Bailey-Bucktrout SL, Lin JC, et al. (2016)ICOS Promotes the Function of CD4(+) Effector T Cells during Anti-OX40-Mediated Tumor Rejection. Cancer Research, 76, 3684-3689.
[4] Kumar P, Marinelarena A, Raghunathan D, Ragothaman VK, Saini S, Bhattacharya P, et al. (2019)Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation. Cellular & Molecular Immunology, 16, 138-153.
[5] Bell RB, Leidner RS, Crittenden MR, Curti BD, Feng ZP, Montler R, et al. (2016)OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment. Oral Oncology, 52, 1-10.
[6] Triplett TA, Tucker CG, Triplett KC, Alderman Z, Sun LH, Ling LE, et al. (2015)STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGF beta Receptor Blockade. Cancer Immunology Research, 3, 526-535.
[7] Malamas AS, Hammond SA, Schlom J, Hodge JW. (2017)Combination of OX40L fusion protein with an anti-tumor vaccine reduces lung metastasis and prolongs survival in a murine model of metastatic triple negative breast cancer. Cancer Research, 77.
[8] Tanabe A, Nakano K, Nakakido M, Nagatoishi S, Tanaka Y, Tsumoto K, et al. (2018)Production and characterization of a novel site-specific-modifiable anti-OX40-receptor single-chain variable fragment for targeted drug delivery. Biochemical and Biophysical Research Communications, 496, 614-620.
[9] Duhen R, Ballesteros-Merino C, Frye AK, Tran E, Rajamanickam V, Chang S-C, et al. (2021)Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nature Communications, 12, 1047.
[10] Thapa B, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, et al. (2024)OX40/OX40 ligand and its role in precision immune oncology. Cancer and Metastasis Reviews.

Sponsors, Associates, and Links

• MEDS Clinical Medicine
  
  
• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Basic Medicine
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine